Skip to main content Skip to search Skip to main navigation

MDR: Proposal for a delay due to Covid-19

The deadline of 26 May 2020 should have been the date: The European Commission's Medical Device Regulation (MDR) was supposed to come into force. Due to the Corona crisis, the European Commission is now submitting a proposal to postpone the implementation deadline.

Other organisations had already called for this step:

Medical device manufacturers have repeatedly questioned whether the deadline can be met, as there is still a lack of Notified Bodies. The introduction of laws to ensure compliance with the new product standards was also critical in terms of timing (we reported).

In a press release of 23 March 2020, MedTech Europe called for a postponement of the introduction date for MDR and IVDR. Their proposal: Six months after the crisis has been overcome, the implementation should be resumed.

In a letter of 24 March 2020, six Members of the European Parliament address the lack of resources caused by the current crisis in the following areas:

  • Approval of clinical trials
  • Notification and auditing of Notified Bodies
  • Manufacturing

The Members of Parliament are calling to maintain the current system for regulating medical devices. Health systems across Europe need all their resources to deal with the corona crisis.

The proposal for postponement should be submitted in early April and implemented as soon as possible. This information is according to a Q&A session at the European Commission press conference of 25 March 2020.


Sources:

MedTech Europe: Press release

European Commission: Letter of the European Parliament

European Commission: Q&A Press conference Covid-19 and MDR

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
EU: Analysis Supporting the Proposed Biotech Act

EU: Analysis Supporting the Proposed Biotech Act

The European Commission has published the analysis underpinning the proposed Biotech Act. The initiative aims to strengthen Europe’s biotechnology and biomanufacturing sectors and to accelerate the development, production and market uptake of biotechnology-based innovations.
Read more
EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the results of its “Annual Regulatory GMP/GDP Inspection Survey 2025”. The data suggest that international GMP inspections are increasingly being replaced by reliance and work-sharing approaches between inspectorates.
Read more
What are the Core Tasks of Human Resource Management?

What are the Core Tasks of Human Resource Management?

Here's the answer:
Read more
European GMP Regulations: Ongoing Changes and What Lies Ahead

European GMP Regulations: Ongoing Changes and What Lies Ahead

At the 2026 ISPE European Annual Conference in Copenhagen, Brendan Cuddy (EMA) provided a concise update on current European GMP regulatory developments and the work of the GMP/GDP Inspectors Working Group (GMDP IWG).
Read more
Previous
Next